New diabetes pill shows promise in early safety trial

NCT ID NCT04426474

Completed Symptom relief Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen May 27, 2026 · Last updated Jun 14, 2026 · Updated 3 times

Summary

This early-stage study tested a new medicine called LY3502970 in 68 adults with type 2 diabetes. The main goal was to check for side effects and see how the body processes the drug. Participants took the medicine for several weeks and had regular blood tests to measure drug levels and blood sugar changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinical Pharmacology of Miami

Hialeah, Florida, 33014, United States
Endeavor Clinical Trials

San Antonio, Texas, 78229, United States
Hassman Research Institute

Marlton, New Jersey, 08053, United States
Midwest Clinical Research Unit

Dayton, Ohio, 45417, United States
Profil Institut für Stoffwechselforschung

Neuss, North Rhine-Westphalia, 41460, Germany
Profil Mainz

Mainz, 55116, Germany

Conditions

Explore the condition pages connected to this study.

DIABETES MELLITUS, TYPE 2